Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Therapy-related core binding factor Acute Myeloid Leukemia – a Study of the french acute leukemia intergroup

View Full Paper
Ask AI
Bookmark
Share

Authors

MCMathilde ChanutTBThorsten BraunMUMadalina Uzunov

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals no difference in cumulative incidence or overall survival in therapy-related CBF-AML compared to de novo cases.

Key Points

  • t-AML patients had a median age of 59 years and similar RUNX1::RUNX1T1 subtype distribution to de novo cases.
  • At a median follow-up of 5.3 years, the cumulative incidence of relapse was 41% for therapy-related CBF-AML patients.
  • Gemtuzumab-ozogamycin was utilized in 9% of therapy-related cases, affecting treatment regimens with intensive chemotherapy.
  • Overall survival rates after multivariable adjustment showed no significant difference between therapy-related and de novo AML patients.

Cite This Study

Chanut et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e5e5https://doi.org/10.1182/blood-2025-37
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Therapy-related AML (t-AML) on the rise: A national perspective on evolving trends, treatment outcomes, and prognostic implications in hospitalized patients2025
  2. 2Therapy related core binding factor Acute Myeloid Leukemia (CBF-AML) responds favorably to fludarabine, cytarabine, GCSF (FLAG) based therapy: Exploratory Analysis from a Phase 2 trial2025
  3. 3Older age and complex karyotype are the main predictors of mortality irrespective of allogeneic transplant in therapy-related myeloid neoplasms: A single‑center retrospective cohort2025
  4. 4Central nervous system involvement in pediatric Acute Myeloid Leukemia: A comprehensive report from the AML-BFM group2025
  5. 5Bzip in-frame mutations might abrogate the adverse prognosis of therapy-related CEBPA-mutated AML2025